Dr Castillo on the Efficacy of Iopofosine I 131 in Waldenström Macroglobulinemia

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, institute physician, Dana-Farber Cancer Institute, associate professor, medicine, Harvard Medical School, discusses the efficacy of treatment with iopofosine I 131 (previously CLR 131) in patients with Waldenström macroglobulinemia.

Topline data from the phase 2 CLOVER WaM trial (NCT02952508) were shared on January 8, 2024, showing that the agent elicited an overall response rate (ORR) of 75.6% and a major response rate (MRR) of 61% (95% CI, 44.50%-75.80%; 2-sided P < .0001), meeting the trial’sprimary end point. Furthermore, the disease control rate was 100% and at a median follow-up of 8 months, the median duration of response (DOR) has not yet been reached. Notably, these data continue to support the 2020 fast track designation of iopofosine I 131, which was granted by the FDA to patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

The data presented on January 8th, 2024, exceeded expectations, Castillo begins. The ORR was also high, and the clinical benefits observed in these patients was substantial, he emphasizes. From a clinical research standpoint, these data support the continued evaluation of therapies to address unmet needs in Waldenström macroglobulinemia, particularly the lack of complete responses (CRs) seen in this disease, he emphasizes. Achieving CRs has been a challenge in Waldenström macroglobulinemia, contrasting with the efficacy of therapies for patients with other hematological conditions, in whom deep responses and minimal residual disease–negative treatment outcomes are more attainable, he states.

In the presented data, an 8% stringent CR rate with iopofosine I 131 was observed, a noteworthy development given that traditional treatments, such as chemotherapy, are the primary inducers of CRs in Waldenström macroglobulinemia clinical trials, Castillo expands.

The efficacy of the regimen is especially interesting considering the targeted patient population, which includes those previously exposed to rituximab (Rituxan)–containing regimens and BTK inhibitors, Castillo continues. This subset of patients has limited treatment options. In the trial, patients underwent a median of 4 prior treatments, according to Castillo. Notably, iopofosine I 131 demonstrated effectiveness in patients regardless of their mutational status, adding an intriguing dimension to this agent’s potential application in clinical practice, he concludes.

spot_img

More from this stream

Recomended

Celebrate the Earth in April with Brochu Walker

April is officially Earth Month, and what better to mark the month than with the super-chic, conscious luxury brand, Brochu Walker? Here’s the low-down on this...

CEO Discusses Q1 Results: Strong Performance with 16% Increase in Net Income

Article 0 Comments The Travelers Companies, Inc. today reported first quarter net income of $1.123 billion, up 16% compared to $975 million in the prior year quarter. Core income in the current...

Choosing the Best CFO Executive Search Firm for Your Business

If the past year has taught us anything, it’s that leadership matters. This is especially true among companies in the Digital Health, Life Sciences, FinTech, and Software & Technology sectors with the myriad challenges and opportunities presented by the pandemic. Whether you are bolstering your C-suite to support continued success and growth or seeking executives […]

The post Selecting the Right CFO Executive Search Firm for Your Company appeared first on Insights Success.

‘ProCook joins forces with Food Cycle charity’

Kitchenware brand ProCook has announced a new partnership with Food Cycle, a UK charity that aims to alleviate food poverty, loneliness and food waste through community dining. The move...

‘Leading VC Firm Raises .2Bn with Focus on AI Industry’

Andreessen Horowitz, a prominent Silicon Valley venture capital group led by veteran tech investors Marc Andreessen and Ben Horowitz, has successfully raised $7.2 billion for investment in tech startups, marking one of the largest fundraising efforts by a venture capital firm in recent years. The funds will be allocated across various new funds, including those […]

The post Silicon Valley VC- Andreesan Horowitz Secures $7.2Bn Focusing on AI Industry appeared first on Insights Success.

‘1GW HyFuels renewable energy portfolio acquired by Nova Clean Energy’

HyFuels comprises wind and solar development projects in mid-to-late-stages alongside an earlier stage green ammonia project, all located on the Texas Gulf Coast Nova Clean Energy has acquired a...